

## Regulatory Story

[Go to market news section](#)



**Company** Fulcrum Pharma PLC  
**TIDM** FUL  
**Headline** Directorate Change  
**Released** 07:00 08-Jun-2009  
**Number** 4897T07

**fulcrumpharma**  
 Providing Expert Solutions

RNS Number : 4897T  
 Fulcrum Pharma PLC  
 08 June 2009

### Fulcrum Pharma plc (the "Company" or "Fulcrum Pharma")

#### Directorate Change

#### **Fulcrum Pharma (AIM:FUL) announces a change in Financial Director. Mr Barry Knight appointed as Chief Financial Officer.**

Fulcrum Pharma announces today that Mr Geoffrey Smith will step down as Finance Director of Fulcrum Pharma on 8 June 2009 and will leave the Company on 30 June 2009. With effect from 8 June 2009 Mr Barry Knight is appointed as Chief Financial Officer and as a Director of Fulcrum Pharma in succession to Mr. Smith. During the overlap period there will be a handover of responsibilities to ensure a smooth transition of the financial leadership role for the Fulcrum Pharma business.

Commenting on the changes Dr Frank M Armstrong, CEO of Fulcrum Pharma said, "*Geoffrey has spent nearly 10 years of his career at Fulcrum Pharma where he has led the finance function, played a key role in the AIM listing and completion of two acquisitions and acted as interim President of the US business. He has made vital contributions to the growth and development of the business. With the new management team in place he feels it is the right time to step down as Fulcrum Pharma moves forward to the next stage of its growth and development. We would like to thank him for his commitment and contribution to Fulcrum Pharma and wish him every success in the future*"

Barry is a Chartered Accountant who qualified at Ernst and Young. He has extensive commercial experience in Financial Accounting and Administration. Most recently he was Finance and Administration Director of KeyMed and CFO of Trigen Ltd and Trigen Holdings AG, where he gained experience of the biotechnology sector, fund raising and mergers & acquisitions.

Commenting on Barry's appointment Mr. Grahame Cook, Chairman of Fulcrum Pharma said, "*I am delighted to welcome Barry as CFO of Fulcrum Pharma. Barry has a distinguished career in finance and will bring substantial healthcare finance experience to the management team and Board of Fulcrum Pharma*".

#### **For further information, please contact:**

##### **Fulcrum Pharma plc**

Frank Armstrong, Chief Executive

Tel: 07815 191565

##### **Seymour Pierce**

Jonathan Wright

Tel: 0207 107 8000

Barry Kenneth Knight, aged 55, is or has in the past five years been a director of the following companies:

#### *Current directorships*

Trigen Holdings Limited (in members voluntary liquidation)  
Trigen Limited (in members voluntary liquidation)

*Past directorships*  
Trigen Holdings AG

**About Fulcrum Pharma plc**

Fulcrum Pharma plc is a professional services company providing clients with expert solutions for the development of therapeutic products. Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange having successfully floated in March 2000.

This information is provided by RNS  
The company news service from the London Stock Exchange

END

BOABLGDLGSGGGCU

CLOSE

**London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.**

©2009 London Stock Exchange plc. All rights reserved

Regulatory